Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx

This article was originally published in Scrip

Executive Summary

In giving its blessing to Eli Lilly & Co. on March 22 to market Taltz (ixekizumab) as a treatment for adults with moderate-to-severe plaque psoriasis, the FDA created a new rivalry for Novartis AG's medicine Cosentyx (secukinumab).


Related Content

Novartis Champions Cosentyx With More Long-Term Psoriasis Data
Novartis Has Blockbuster Targets For Cosentyx In New Autoimmune Indications
Lilly Math: Subtracting Employees And Animal Health Equals Pharma Growth
Quick Commercial Standouts Lacking Among 2016 US Launches
Sponsors Flesh Out Profiles of New Dermatology Drugs At AAD Meeting
Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts